Chemistry:CR-4056
From HandWiki
Short description: Investigational analgesic drug
 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C17H12N4 |
| Molar mass | 272.311 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
CR-4056 is an analgesic drug candidate with a novel mechanism of action, acting as a ligand for the imidazoline receptor I2. It showed promising results in animal studies against various types of neuropathic pain, and has reached Phase II human clinical trials as a potential treatment for pain associated with osteoarthritis.[1][2][3][4][5]
See also
References
- ↑ "Analgesic efficacy of CR4056, a novel imidazoline-2 receptor ligand, in rat models of inflammatory and neuropathic pain". Journal of Pain Research 4: 111–25. 2011. doi:10.2147/JPR.S18353. PMID 21647215.
- ↑ "Antihyperalgesic effects of imidazoline I(2) receptor ligands in rat models of inflammatory and neuropathic pain". British Journal of Pharmacology 171 (6): 1580–90. March 2014. doi:10.1111/bph.12555. PMID 24329196.
- ↑ "Efficacy of CR4056, a first-in-class imidazoline-2 analgesic drug, in comparison with naproxen in two rat models of osteoarthritis". Journal of Pain Research 10: 1033–1043. May 4, 2017. doi:10.2147/JPR.S132026. PMID 28496359.
- ↑ "2 receptors: An update". Pharmacology & Therapeutics 178: 48–56. October 2017. doi:10.1016/j.pharmthera.2017.03.009. PMID 28322973.
- ↑ "A Randomized, Placebo-Controlled, Double-Blind, Phase II Clinical Trial of the First-in-Class Imidazoline-2 Receptor Ligand CR4056 in Pain from Knee Osteoarthritis and Disease Phenotypes". Arthritis Rheumatol (2017 ACR/ARHP Annual Meeting, Abstract 1193) 69 (suppl 10). 2017.
 |  |
